Perspectives on osteoporosis therapies

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Endocrinological Investigation

• Publication date

  2015-01-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40618-014-0236-9PMID 25577263
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Odanacatib Treatment Affects Trabecular and Cortical Bone in the Femur of Postmenopausal Women: Results of a Two‐Year Placebo‐Controlled Trial

  2015cited by this paper
• Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

  2015cited by this paper
• Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis

  2015cited by this paper
• A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

  2015cited by this paper
• microRNA‐103a Functions as a Mechanosensitive microRNA to Inhibit Bone Formation Through Targeting Runx2

  2015cited by this paper
• Effect of ONO‐5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2‐Year Results From the OCEAN Study

  2014cited by this paper
• Single‐ and Multiple‐Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women

  2014cited by this paper
• A novel 11β-HSD1 inhibitor improves diabesity and osteoblast differentiation.

  2014cited by this paper
• A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis.

  2014cited by this paper
• Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns

  2014cited by this paper
• Romosozumab in postmenopausal women with low bone mineral density

  2014cited by this paper
• The osteocyte as a therapeutic target in the treatment of osteoporosis

  2014cited by this paper
• Vitamin K2 Therapy for Postmenopausal Osteoporosis

  2014cited by this paper
• Effect of odanacatib on BMD and fractures: estimates from Bayesian univariate and bivariate meta-analyses.

  2014cited by this paper
• Romosozumab in postmenopausal women with osteopenia.

  2014cited by this paper
• Soluble guanylate cyclase as a novel treatment target for osteoporosis.

  2014cited by this paper
• Tryptophan hydroxylase 1 (Tph-1)-targeted bone anabolic agents for osteoporosis.

  2014cited by this paper
• GLP-1: benefits beyond pancreas

  2014cited by this paper
• Role of miRNAs in bone and their potential as therapeutic targets.

  2014cited by this paper
• A Phase IB multicentre dose‐determination study of BHQ880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events

  2014cited by this paper
• Treatment of post-menopausal osteoporosis: beyond bisphosphonates

  2014cited by this paper
• The Effect of the Cathepsin K Inhibitor ONO‐5334 on Trabecular and Cortical Bone in Postmenopausal Osteoporosis: The OCEAN Study

  2014cited by this paper
• Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial.

  2014cited by this paper
• Sirtuin1 (Sirt1) Promotes Cortical Bone Formation by Preventing β-Catenin Sequestration by FoxO Transcription Factors in Osteoblast Progenitors*

  2014cited by this paper
• Pharmacological inhibition of PPARγ increases osteoblastogenesis and bone mass in male C57BL/6 mice

  2013cited by this paper
• Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence

  2013cited by this paper
• Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriers

  2013cited by this paper
• 11β-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction.

  2013cited by this paper
• Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism

  2013cited by this paper
• Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.

  2013cited by this paper
• Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women

  2013cited by this paper
• Long-term resveratrol treatment prevents ovariectomy-induced osteopenia in rats without hyperplastic effects on the uterus

  2013cited by this paper
• Activin receptor signaling: a potential therapeutic target for osteoporosis.

  2012cited by this paper
• Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys

  2012cited by this paper
• Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey

  2012cited by this paper
• Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study

  2012cited by this paper
• Comparison of the skeletal effects induced by daily administration of PTHrP (1–36) and PTHrP (107–139) to ovariectomized mice

  2012cited by this paper
• Osteoprotection by semaphorin 3A

  2012cited by this paper
• GSK-3 inhibition by an orally active small molecule increases bone mass in rats.

  2012cited by this paper
• Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

  2011cited by this paper
• A Rate-Limiting Role for Dickkopf-1 in Bone Formation and the Remediation of Bone Loss in Mouse and Primate Models of Postmenopausal Osteoporosis by an Experimental Therapeutic Antibody

  2011cited by this paper
• Safety and efficacy of the cathepsin K inhibitor ONO‐5334 in postmenopausal osteoporosis: The OCEAN study

  2011cited by this paper
• Glycogen synthase kinase‐3α/β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage

  2011cited by this paper
• Dickkopf‐1 regulates bone formation in young growing rodents and upon traumatic injury

  2011cited by this paper
• The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.

  2011cited by this paper
• Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover

  2011cited by this paper
• The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.

  2011cited by this paper
• Inhibition of gut-derived serotonin synthesis: a potential bone anabolic treatment

  2010cited by this paper
• Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect

  2010cited by this paper
• Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial

  2010cited by this paper
• Single‐Dose, Randomized, Double‐Blind, Placebo‐Controlled Study of ACE‐011 (ActRIIA‐IgG1) in Postmenopausal Women

  2009cited by this paper
• Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double‐Blind, Randomized, Placebo‐Controlled Phase I Studies

  2009cited by this paper
• Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD.

  2009cited by this paper
• Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density

  2009cited by this paper
• The Src Inhibitor AZD0530 Reversibly Inhibits the Formation and Activity of Human Osteoclasts

  2009cited by this paper
• The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

  2008cited by this paper
• Deletion of a Single Allele of the Dkk1 Gene Leads to an Increase in Bone Formation and Bone Mass

  2006cited by this paper
• Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia.

  2006cited by this paper
• Bone mineral density in sclerosteosis; affected individuals and gene carriers.

  2005cited by this paper
• Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

  2005cited by this paper
• Intracellular Machinery for Matrix Degradation in Bone‐Resorbing Osteoclasts

  2004cited by this paper
• Epidemiology and outcomes of osteoporotic fractures.

  2002cited by this paper
• Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).

  2001cited by this paper
• Osteoporosis prevention, diagnosis, and therapy.

  2001cited by this paper
• Decreased C-Src Expression Enhances Osteoblast Differentiation and Bone Formation

  2000cited by this paper
• Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice.

  1991cited by this paper

• The METTL14/YTHDF3 axis regulates EPSTI1-mediated osteogenic differentiation of human bone marrow mesenchymal stem cells.

  2026cites this paper
• The Effect of Oxytocin on Osteoporosis Improvement: A Systematic Review

  2024cites this paper
• Plasma proteins, circulating metabolites mediate causal inference studies on the effect of gut bacteria on the risk of osteoporosis development.

  2024cites this paper
• The Interplay Between Oral-Gut Microbiome and Bone Health: A Comprehensive Review

  2024cites this paper
• Identification of gravity-responsive proteins in the femur of spaceflight mice using a quantitative proteomic approach.

  2023cites this paper
• Autologous Tooth Graft: Innovative Biomaterial for Bone Regeneration. Tooth Transformer® and the Role of Microbiota in Regenerative Dentistry. A Systematic Review

  2023cites this paper
• Relationships between prescribed anti-osteoporotic treatment and necessity-concerns assessment: a psychological network analysis

  2023cites this paper
• Exploring the regulatory mechanism of osteoporosis based on intestinal flora: A review

  2022cites this paper
• Rapid ovarian transcript changes during the onset of premature ovarian insufficiency in a mouse model

  2022cites this paper
• Briarane-type diterpenoids, the inhibitors of osteoclast formation by interrupting Keap1-Nrf2 interaction and activating Nrf2 pathway.

  2022cites this paper
• Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates

  2021cites this paper
• Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.

  2020cites this paper
• Gut Microbiome Reveals Specific Dysbiosis in Primary Osteoporosis

  2020cites this paper
• CircFOXP1/FOXP1 promotes osteogenic differentiation in adipose‐derived mesenchymal stem cells and bone regeneration in osteoporosis via miR‐33a‐5p

  2020cites this paper
• Induction of Lrp5 HBM-causing mutations in Cathepsin-K expressing cells alters bone metabolism.

  2019cites this paper
• Icariin promotes osteogenic differentiation by suppressing Notch signaling.

  2019cites this paper
• Main Resveratrol Action Mechanisms in Postmenopausal Osteoporosis

  2019cites this paper
• Oviductus Ranae protein hydrolyzate prevents menopausal osteoporosis by regulating TGFβ/BMP2 signaling

  2019cites this paper
• Osteoporosis therapies might lead to intervertebral disc degeneration via affecting cartilage endplate.

  2019cites this paper
• Primary cilium is required for the stimulating effect of icaritin on osteogenic differentiation and mineralization of osteoblasts in vitro

  2017cites this paper
• Icariin improves osteoporosis, inhibits the expression of PPARγ, C/EBPα, FABP4 mRNA, N1ICD and jagged1 proteins, and increases Notch2 mRNA in ovariectomized rats

  2017cites this paper
• Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy

  2017cites this paper
• RANKL-induced osteoclastogenesis is suppressed by 4-O-methylhonokiol in bone marrow-derived macrophages

  2017cites this paper
• Thiol/disulfide homeostasis in postmenopausal osteoporosis

  2017cites this paper
• New therapies in osteoporosis

  2016cites this paper
• Stimulation of cortical bone formation with thienopyrimidine based inhibitors of Notum Pectinacetylesterase.

  2016cites this paper
• Effects of a Combination Therapy of Sclerostin Antibody III and Raloxifene on Bone Formation Markers in Ovariectomized Rats.

  2016cites this paper
• Key words postmenopausal women , osteoporosis , bone density , pharmacological therapy , fracture

  2016cites this paper
• 7. Novel and current approaches to dietary and non-dietary bone metabolism regulation

  2016cites this paper
• The role of mesothelin (MSLN) in bone homeostasis

  2016cites this paper
• The topographical properties of silica nanoparticle film preserve the osteoblast-like cell characteristics in vitro

  2016cites this paper
• Nuevas terapias en osteoporosis

  2016cites this paper
• Efficacy of Intraperitoneal Administration of PEGylated NELL-1 for Bone Formation

  2016cites this paper
• Efficacy of Intraperitoneal Administration of PEGylated NELL-1 for Bone Formation.

  2016cites this paper
• A view at monoclonal antibodies in therapy of osteoporosis

  2015cites this paper
• Bone health in type 1 diabetes: focus on evaluation and treatment in clinical practice

  2015cites this paper